Description
Nadunolimab is a monoclonal antibody designed to treat colorectal cancer by targeting specific immune pathways. It functions as an immunotherapy agent that works to enhance the body's natural immune response against cancer cells.
Mechanism of Action
Nadunolimab blocks inhibitory signals that prevent immune cells from effectively attacking cancer tissue. This allows T-cells and other immune effector cells to better recognize and eliminate malignant cells in colorectal tumors.
Side Effects
Fatigue
Nausea
Diarrhea
Skin rash
Decreased appetite
Fever
Infusion reactions
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07281716
Phase 1
Recruiting
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
United States